Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

T. Scott Stroup, Jeffrey A. Lieberman, Joseph Patrick McEvoy, Marvin S. Swartz, Sonia M. Davis, Robert A. Rosenheck, Diana O. Perkins, Richard S.E. Keefe, Clarence E. Davis, Joanne Severe, John K. Hsiao

Research output: Contribution to journalArticle

323 Citations (Scopus)

Abstract

Background: In the treatment of schizophrenia, changing antipsychotics is common when one treatment is suboptimally effective, but the relative effectiveness of drugs used in this strategy is unknown. This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic. Method: Subjects with schizophrenia (N=444) who had discontinued the atypical antipsychotic randomly assigned during phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigation were randomly reassigned to double-blind treatment with a different antipsychotic (olanzapine, 7.5-30 mg/ day [N=66]; quetiapine, 200-800 mg/day [N=63]; risperidone, 1.5-6.0 mg/day [N= 69]; or ziprasidone, 40-160 mg/day [N= 135]). The primary aim was to determine if there were differences between these four treatments in effectiveness measured by time until discontinuation for any reason. Results: The time to treatment discontinuation was longer for patients treated with risperidone (median: 7.0 months) and olanzapine (6.3 months) than with quetiapine (4.0 months) and ziprasidone (2.8 months). Among patients who discontinued their previous antipsychotic because of inefficacy (N=184), olanzapine was more effective than quetiapine and ziprasidone, and risperidone was more effective than quetiapine. There were no significant differences between antipsychotics among those who discontinued their previous treatment because of intolerability (N=168). Conclusions: Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason.

Original languageEnglish (US)
Pages (from-to)611-622
Number of pages12
JournalAmerican Journal of Psychiatry
Volume163
Issue number4
DOIs
StatePublished - Jan 1 2006

Fingerprint

olanzapine
Risperidone
Antipsychotic Agents
Schizophrenia
Therapeutics
Clinical Trials, Phase I
ziprasidone
Quetiapine Fumarate
Double-Blind Method

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. / Stroup, T. Scott; Lieberman, Jeffrey A.; McEvoy, Joseph Patrick; Swartz, Marvin S.; Davis, Sonia M.; Rosenheck, Robert A.; Perkins, Diana O.; Keefe, Richard S.E.; Davis, Clarence E.; Severe, Joanne; Hsiao, John K.

In: American Journal of Psychiatry, Vol. 163, No. 4, 01.01.2006, p. 611-622.

Research output: Contribution to journalArticle

Stroup, T. Scott ; Lieberman, Jeffrey A. ; McEvoy, Joseph Patrick ; Swartz, Marvin S. ; Davis, Sonia M. ; Rosenheck, Robert A. ; Perkins, Diana O. ; Keefe, Richard S.E. ; Davis, Clarence E. ; Severe, Joanne ; Hsiao, John K. / Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. In: American Journal of Psychiatry. 2006 ; Vol. 163, No. 4. pp. 611-622.
@article{c1c58cd98f424aa395b85d6eb2135520,
title = "Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic",
abstract = "Background: In the treatment of schizophrenia, changing antipsychotics is common when one treatment is suboptimally effective, but the relative effectiveness of drugs used in this strategy is unknown. This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic. Method: Subjects with schizophrenia (N=444) who had discontinued the atypical antipsychotic randomly assigned during phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigation were randomly reassigned to double-blind treatment with a different antipsychotic (olanzapine, 7.5-30 mg/ day [N=66]; quetiapine, 200-800 mg/day [N=63]; risperidone, 1.5-6.0 mg/day [N= 69]; or ziprasidone, 40-160 mg/day [N= 135]). The primary aim was to determine if there were differences between these four treatments in effectiveness measured by time until discontinuation for any reason. Results: The time to treatment discontinuation was longer for patients treated with risperidone (median: 7.0 months) and olanzapine (6.3 months) than with quetiapine (4.0 months) and ziprasidone (2.8 months). Among patients who discontinued their previous antipsychotic because of inefficacy (N=184), olanzapine was more effective than quetiapine and ziprasidone, and risperidone was more effective than quetiapine. There were no significant differences between antipsychotics among those who discontinued their previous treatment because of intolerability (N=168). Conclusions: Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason.",
author = "Stroup, {T. Scott} and Lieberman, {Jeffrey A.} and McEvoy, {Joseph Patrick} and Swartz, {Marvin S.} and Davis, {Sonia M.} and Rosenheck, {Robert A.} and Perkins, {Diana O.} and Keefe, {Richard S.E.} and Davis, {Clarence E.} and Joanne Severe and Hsiao, {John K.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1176/ajp.2006.163.4.611",
language = "English (US)",
volume = "163",
pages = "611--622",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "4",

}

TY - JOUR

T1 - Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

AU - Stroup, T. Scott

AU - Lieberman, Jeffrey A.

AU - McEvoy, Joseph Patrick

AU - Swartz, Marvin S.

AU - Davis, Sonia M.

AU - Rosenheck, Robert A.

AU - Perkins, Diana O.

AU - Keefe, Richard S.E.

AU - Davis, Clarence E.

AU - Severe, Joanne

AU - Hsiao, John K.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Background: In the treatment of schizophrenia, changing antipsychotics is common when one treatment is suboptimally effective, but the relative effectiveness of drugs used in this strategy is unknown. This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic. Method: Subjects with schizophrenia (N=444) who had discontinued the atypical antipsychotic randomly assigned during phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigation were randomly reassigned to double-blind treatment with a different antipsychotic (olanzapine, 7.5-30 mg/ day [N=66]; quetiapine, 200-800 mg/day [N=63]; risperidone, 1.5-6.0 mg/day [N= 69]; or ziprasidone, 40-160 mg/day [N= 135]). The primary aim was to determine if there were differences between these four treatments in effectiveness measured by time until discontinuation for any reason. Results: The time to treatment discontinuation was longer for patients treated with risperidone (median: 7.0 months) and olanzapine (6.3 months) than with quetiapine (4.0 months) and ziprasidone (2.8 months). Among patients who discontinued their previous antipsychotic because of inefficacy (N=184), olanzapine was more effective than quetiapine and ziprasidone, and risperidone was more effective than quetiapine. There were no significant differences between antipsychotics among those who discontinued their previous treatment because of intolerability (N=168). Conclusions: Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason.

AB - Background: In the treatment of schizophrenia, changing antipsychotics is common when one treatment is suboptimally effective, but the relative effectiveness of drugs used in this strategy is unknown. This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic. Method: Subjects with schizophrenia (N=444) who had discontinued the atypical antipsychotic randomly assigned during phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigation were randomly reassigned to double-blind treatment with a different antipsychotic (olanzapine, 7.5-30 mg/ day [N=66]; quetiapine, 200-800 mg/day [N=63]; risperidone, 1.5-6.0 mg/day [N= 69]; or ziprasidone, 40-160 mg/day [N= 135]). The primary aim was to determine if there were differences between these four treatments in effectiveness measured by time until discontinuation for any reason. Results: The time to treatment discontinuation was longer for patients treated with risperidone (median: 7.0 months) and olanzapine (6.3 months) than with quetiapine (4.0 months) and ziprasidone (2.8 months). Among patients who discontinued their previous antipsychotic because of inefficacy (N=184), olanzapine was more effective than quetiapine and ziprasidone, and risperidone was more effective than quetiapine. There were no significant differences between antipsychotics among those who discontinued their previous treatment because of intolerability (N=168). Conclusions: Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason.

UR - http://www.scopus.com/inward/record.url?scp=85047695988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047695988&partnerID=8YFLogxK

U2 - 10.1176/ajp.2006.163.4.611

DO - 10.1176/ajp.2006.163.4.611

M3 - Article

VL - 163

SP - 611

EP - 622

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 4

ER -